Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: favourite (50), preference (97)

RCHOP(14)-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine (14) Ver 1.2

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-DOXORUBICIN-PREDNISOLONE-RITUXIMAB-VINCRISTINE- (14) (RCHOP 14) There are mult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCHOP14-Cyclophosphamide-Doxorubicin-Prednisolone-Rituximab-Vincristine-14-Ver-1.2.pdf

InP-Ifosfamide-Liposomal Doxorubicin (Caelyx) v1

Description: Chemotherapy Protocol SARCOMA IFOSFAMIDE-LIPOSOMAL DOXORUBICIN (Caelyx) In-Patient Regimen Please note this protocol is based on information for the us
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/InP-Ifosfamide-Liposomal-Doxorubicin-Caelyx-v1.pdf

E(100)CT

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-EPIRUBICIN (100) Regimen (E100CT) • Breast Cancer – Cyclophosp
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/E100CT.pdf

Engaging for increased research participation - full report

Description: Engaging for increased research participation Public and healthcare professionals' perceptions For further information contact: Chris Stock Head of R&D communications
Url: /Media/Southampton-Clinical-Research/Marketresearch/Engaging-for-increased-research-participation-full-report-v2.pdf

Epcoritamab -Cycle 1 (Priming)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB -Cycle 1 - (28 Day -Priming) Regimen • Lymphoma-Epcoritamab – Cycle 1- (28 day -Priming) Indication •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-1-Priming-Ver1.pdf

AtezolizumabSC Bevacizumab Carboplatin Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ATEZOLIZUMAB-SC-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen • Lung-Atezolizumab-SC-Bevacizumab-Carbop
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AtezolizumabSC-Bevacizumab-Carboplatin-Paclitaxel-Ver1.0.pdf

Atezolizumab-Carboplatin(AUC5)-Etoposide(IV/PO)

Description: Chemotherapy Protocol LUNG CANCER– SMALL CELL (SCLC) ATEZOLIZUMAB-CARBOPLATIN (AUC5)-ETOPOSIDE(IV/PO) Regimen  Lung - Atezolizumab-Carboplatin (AUC5)-Etoposide(IV/
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Atezolizumab-CarboplatinAUC5-EtoposideIVPO.pdf

Papers Trust Board 28 March 2019

Description: Agenda Group Name: Date of Meeting: Venue: Time: Apologies to: Trust Board – Open Session 28 March 2019 Conference Room
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2019/Papers-Trust-Board-28-March-2019.pdf

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

Paclitaxel (7 day)

Description: Chemotherapy Protocol BLADDER CANCER PACLITAXEL (7 day) Regimen • Bladder Cancer – Paclitaxel (7 day) Indication • Treatment of locally advanced or metastatic bladder
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Paclitaxel-7-day.pdf

81 to 90 of 404

Previous … 7 8 9 10 11 … Next